BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Feature

The Frontier That Won’t Quite Arrive

Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep...

June 26, 2026 | Analysis

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

Security at What Cost? APAC and the Great Supply-Chain Reordering

For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...

June 24, 2026 | Analysis

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

World-Class Plants, Who Will Run Them? APAC's Biomanufacturing Skills Gap

Walk into one of the gleaming new large-molecule plants going up across Songdo, Tuas or Hyderabad and the first impression is of inevitability. The...

June 18, 2026 | Analysis

Agility or Corner-Cutting? Asia's Accelerated-Approval Gamble

On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, ev...

June 17, 2026 | Analysis

Good Enough and Cheap, or Prove It's Equivalent? Asia's Biosimilar Trust Gap

There is a number that captures Asia's biosimilar paradox in a single line. According to Samsung Bioepis's quarterly tracking of the United States market, ...

June 15, 2026 | Analysis

AI Must Shift Healthcare From Crisis Response To Early Intervention Across APAC

As healthcare systems across Asia Pacific confront mounting workforce shortages, ageing populations, and rising chronic disease burdens, artificial intelli...

June 10, 2026 | News

The Footnote Test: When the Sustainability Pledge Met the Earnings Call

The slide had been on the screen for almost a minute, and no one in the room would meet its eye. It was a simple chart, the kind that the company's invest...

June 04, 2026 | Analysis

Innovation Powerhouse or Inflated Bubble? Reading China’s First-in-Class Boom

A decade ago, the phrase “Chinese first-in-class drug” would have drawn a raised eyebrow in any Western boardroom. China made generics, copied ...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

When America Builds a Wall: Who Inherits China’s Displaced Biotech Work?

When President Trump signed the FY2026 National Defense Authorization Act on December 18, 2025, the biopharmaceutical industry finally got the law it had s...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

Engineering Precision In Chromatography From Development To Commercial Scale

Chromatography in Bioprocessing For pilot and commercial purification of monoclonal antibodies and recombinant proteins, chromatography remains the centra...

April 24, 2026 | Analysis

Can AI close the MSK inequality gap? Improving access to musculoskeletal care in the UK

Behind these statistics lies a deeper and more troubling social divide: that the greatest burden is carried by those in our most deprived communities and m...

April 14, 2026 | Opinion | By Peter Grinbergs, Chief Medical Officer and Co‑founder of EQL

Stay Connected